Placebo for Ezetimibe
Sponsors
Merck Sharp & Dohme LLC, Sanofi, Organon and Co
Conditions
Familial HypercholesterolemiaHypercholesterolemia
Phase 3
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
CompletedNCT02715726
Start: 2016-07-27End: 2018-08-06Updated: 2019-09-30
A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)
CompletedNCT02741245
Start: 2016-06-09End: 2017-01-18Updated: 2024-05-16
Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)
CompletedNCT03867318
Start: 2000-04-24End: 2001-11-16Updated: 2024-05-10
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)
CompletedNCT03884452
Start: 2000-05-03End: 2001-05-24Updated: 2024-05-10
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
CompletedNCT06450366
Start: 2024-07-08End: 2025-03-28Updated: 2026-03-27
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia
CompletedCTIS2023-504920-25-00
Start: 2024-08-23End: 2025-02-27Target: 70Updated: 2025-02-20